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Abstract
To test a two-step approach for radioimmunotargeting of renal cell 
cancer, quadroma cells secreting antichelate X anti-renal cell carcinoma 
bispecific antibodies were obtained by somatic cell fusion. Five monoclo­
nal antibodies against the chelate l,4,7-triazaheptane-A^N',/V"-pentaace- 
tic acid (DTPA) were produced and characterized. Competitive binding 
assays indicated that the anti-DTPA antibodies reacted with DTPA che­
lated with indium, yttrium, chromium, iron, or zinc. The affinity constants 
of the anti-DTPA antibodies for m In-DTPA ranged from 0.19 to 0.23 
nM_1, Using different chelates, a remarkable chelate specificity of the 
anti-DTPA antibodies was demonstrated. The chelates recognized by the 
antibodies DTInl, DTIn2, and DTIn4 share a A^N'^-diacetic acid group, 
whereas the chelates recognized by DTIn3 share a N *-acetic acid group, 
suggesting the presence of different essential structures within the DTPA 
molecule that determine the reactivity of the antibodies.
Five anti-DTPA antibody-producing hvbridomas were used for somatic 
cell fusion with hybridoma G250 directed against renal cell carcinoma, 
resulting in three bispecific antibody-producing quadroma cell lines. The 
bispecific monoclonal antibodies were purified from ascites fluid using 
protein A affinity chromatography followed by hydroxylapatite chroma­
tography and/or cation exchange chromatography. Of the total IgG 
amount present in the ascites fluid, 10-15% represented the bispecific 
antibodies« These bispecific antibodies will allow testing and optimization 
of a two-step approach for radioimmunotargeting of chelated radionu­
clides.
Introduction
Although radiolabeled antitumor antibodies can target tumors se­
lectively in vivo , optimal visualization is delayed for several days, 
because the antibody has to clear from the blood pool and normal 
tissues. In addition to obscuring visualization of tumors, sustained 
levels o f radiolabeled antibody in the blood and normal tissues in­
crease toxicity to nontarget tissues and limit the amount of radioac­
tivity that can be administered in radioim mu no therapy.
The efficacy of radioimmunodetection or radio immunotherapy 
might be optimized by: (a) enhancing tumor uptake; or (b) reducing 
background activity. The use of antibody fragments with faster blood 
clearance ( 1- 3) or antiantibodies to reduce serum levels of circulating 
antibody (4 -6 )  has resulted in reduction of background activity.
Alternatively, reduction of background activity might be accom­
plished by pretargeting protocols. In these, the antitumor antibody is 
administered and allowed to clear from the circulation, after which the 
radionuclide is given as a low-molecular-weight ligand. The main 
advantage of these protocols is the very rapid excretion of the small 
ligand when not targeted to the tumor. The avid interaction between 
biotin and streptavidin has been exploited in such a multi step ap­
proach (7-10). Analogously, pretargeting protocols may make use of 
bispecific antibodies and radiometal-labeled chelates. In this ap~
1 Presented at the “Fifth Conference on Radioimmunodetection and Radioimmuno- 
therapy of Cancer,” October 6 -8 ,  1994, Princeton, NJ. Supported by Research Grant 
93-539 from the Dutch Cancer Society.
2 To whom requests for reprints should be addressed.
proach, the tumor is pretargeted with bispecific antibodies reactive 
with a tumor-associated antigen and with a radiolabeled chelate. The 
feasibility of this approach has been shown in studies in nude mouse 
models ( 1 1 , 12 ) and in immunoscintigraphy studies in colon carci­
noma (13, 14) and medullary thyroid cancer patients (15). The marked 
reduction of the background activity and the good retention of the 
radionuclide in the tumors observed in these studies suggest that this 
approach also could be used for radioimmunotherapeutic purposes.
Bispecific antibodies can be produced either by: (a) chemical 
coupling of two antibody fragments; or (b ) fusion of two hybridoma 
cell lines, resulting in quadromas (16). Chemical production of bispe­
cific antibodies suffers from batch-to-batch variation, whereas 
quadromas are infinite sources of bispecific antibodies. In addition, 
the fusion technique results in quadromas that synthesize, assemble, 
and secrete bispeciftc antibodies by the same process as native im­
munoglobulins.
To investigate the possibilities of a two-phase radioimmunotarget­
ing protocol, we have produced hybridomas secreting M Abs3 specific 
for the chelate DTPA and fused these to a hybridoma producing a 
MAb recognizing a renal cell carcinoma-associated antigen. In this 
report, we describe the isolation and characterization of anti-DTPA 
MAbs, the production of quadromas, and the purification of bsMAbs.
Materials and Methods
Antibodies and Chelates
Production of Protein-Chelate Conjugates. KLH (Pierce, Rockford, IL) 
und BSA (Sigma Chemical Co., St. Louis, MO) were conjugated with the 
cyclic anhydride of DTPA (Sigma) according to the method of Hnatowich et 
al (17). After PD10 (Pharmacia, Uppsala, Sweden) chromatography to remove 
unreacted DTPA, excess InCl3 (Merck, Darmstadt, Germany) or YC13 (Aldrich 
Chemical Co., Milwaukee,WI) was added. Free In3 + or Y3+ was removed by 
PD10 column chromatography.
BSA, fibrinogen (ICN Biochemicals, Costa Mesa, CA), and calf lens protein 
(a kind gift from Dr. W. de Jong, University of Nijmegen, Nijmegen, the 
Netherlands) were conjugated with ITC-Bz-DTPA (kindly provided by Dr. G. 
Griffiths, Iinmunomedics, Moms Plains, NJ) according to the method of 
Ruegg et al (18). BSA and calf lens protein were conjugated with ITC-Bz- 
DOTA (kindly provided by Dr. 0 . A. Gansow, National Cancer Institute, 
Bethesda, MD) according to the method of Ruegg et al. (18).
Preparation of 111In-DTPA. Five /¿I 11 ^ nC^ (Mallinckrodt, Petten, the 
Netherlands) and 2 ¿¿1 InCl3 (2.5 ng/juil) were diluted in 50 fü 40 ihm HCl and 
mixed with 850 ¡jl\ aqueous DTPA solution (0.05 jxg/ml) and 100 ¡x\ 0.1 M 
sodium acetate buffer (pH 6), resulting in a final pH of 3.0. Following 30 min 
of incubation at room temperature, the solution was neutralized with 17 /xl 0.1 
M NaOH. Complexing of In3+ was assessed by paper chromatography on 
Whatman 1 paper with methanol:water (55:45) as an eluent. The specific 
activity of the u , In~DTPA was 700-800 Ci/mmol.
Anti-DTPA Antibodies. BALB/c mice were immunized with an emulsion 
of 50 jug In-DTPA-KLH or Y-DTPA-KLH in complete Freund’s adjuvant
___
• The abbreviations used are: MAb, monoclonal antibody; DTPA, 1,4,7-triazaheptane- 
N,N',A/"-penlaacetic acid; bs, bispecific; KLH, keyhole limpet hemocyanin; ITC-Bz, 
isothiocyanato-benzyl; DOTA, l,4,7,10-tetraazadodecane-A'f)//',iV",Ar-tetraacetic acid.
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(Sigma). Animals received boosters of antigen mixed with incomplete 
Freund’s adjuvant. Three days after an i.v. boost of antigen, spleen cells were 
harvested and fused with Sp2/0-Agl4 myeloma cells (19) as described by Lane 
(20). Culture supematants of resulting clones were analyzed for anti-DTPA 
reactivity using a direct antigen-binding ELISA. Cells of clones reactive with 
In- or Y-DTPA-BSA were subcloned at least twice in soft agarose (30 g/1; 
agarose type VII; Sigma) containing RPMI 1640 medium with hypoxanthine- 
thymidine supplement (GIBCO-BRL, Gaithersburg, MD).
Production of bsMAbs. Enzyme-deficient hybridomas were isolated to 
enable selection of fused cells (21). Hypoxanthine guanine phosphoribosyl 
transferase deficiency was introduced in the anti-DTPA MAb-producing hy­
bridomas by 8-azaguanidine (Sigma) selection. The anti-renal cell carcinoma 
MAb G250 was used as the antitumor antibody in these studies. MAb G250 
and its subclass variants are directed against the renal cell carcinoma-associ­
ated antigen G250 that is expressed homogeneously in 15% of renal cell 
carcinomas, whereas expression in normal tissues is restricted to gastric 
mucosal cells and cells of the larger bile ducts (22). MAb G250 has shown 
excellent targeting of renal cell carcinoma in patients (23). Thymidine kinase- 
deficient hybridoma G250 variants were isolated by bromodeoxyuridine (Boehr- 
inger Mannheim, Mannheim, Germany) selection. Anti-DTPA hybridomas were 
fused with hybridoma G250 at a 1:1 ratio and seeded in soft agarose containing 
low-protein hybridoma medium (GIBCO-BRL) with hypoxanthine-aminopterin- 
thymidine supplement (GIBCO-BRL). Growing colonies were picked, grown in 
suspension, and tested for the production of bsMAb by a double-specificity 
ELISA. Positive clones were recloned at least twice.
ELISAs
In all the assays described in this section, the following conditions were 
used, unless indicated otherwise. Wells of 96-well microtiter plates (Costar, 
Cambridge, MA) were coated overnight at 4°C, and remaining protein binding 
sites were blocked for 1 h with 50 him phosphate buffer (pH 7.4)/150 mM 
NaCl/BSA (5 g/liter). Wells were rinsed wiLh the same buffer. Peroxidase 
activity was revealed using 3,3',5,5'-tetramethylbenzidine (Merck)/H20 2 for 
10-20 min, and A was determined at 450 nm.
Direct Antigen-binding Assay. Wells coated with 400 ng DTPA-BSA, 
600 ng ITC-Bz-DTPA-fibrinogen, or 300 ng ITC-Bz-DOTA-calf lens protein 
were incubated with the culture supernatant, washed, and incubated with 
peroxidase-conjugated rabbit antimouse immunoglobulins (Dakopatts, 
Glostrup, Denmark).
Competitive Antigen-binding Assay. Wells were coated with In-DTPA- 
BSA. Serially diluted Cr-DTPA, Fe-DTPA, Zn-DTPA, Y-DTPA, or In-DTPA 
was added simultaneously with anti-DTPA tissue culture supernatant. After 3 
h of incubation, wells were washed and incubated with peroxidase-conjugated 
rabbit antimouse immunoglobulins.
Double-Specificity ELISA. Wells coated with 400 ng In-DTPA-BSA were 
incubated with serially diluted quadroma tissue culture supernatant, washed, 
and incubated with biotinylated NUHS2. NUH82 (IgGl) is an internal-image, 
anti-idiotype MAb resembling MAb G250 antigen with an affinity-binding 
constant of 8.2 nM_1 for MAb G250 (24). Wells were incubated with a 
strcptavidin-biotinylated horseradish peroxidase complex (Amersham, Little 
Chalfont, England). This assay assured measurement of bispecific antibodies 
with functional DTPA- and G250-binding pockets only. The detection limit 
was determined to be 100 ng bsMAb/ml.
Determination of Isotypes. The isotypes of the anti-DTPA MAbs were 
determined in an ELISA with mouse subclass IgG-specific antisera (Southern 
Biotechnology Associates, Inc., Birmingham,, AL).
Determination of Affinity Constants. Affinity constants for m In-DTPA 
were determined by Scatchard analysis (25). Microtiter wells coated with 
rabbit antimouse immunoglobulins (Dakopatts) were incubated with excess 
anti-DTPA MAb or bsMAb. Increasing amounts of in In-DTPA were added, 
and after 1 h at room temperature, wells were washed and counted.
Purification o f  MAbs
Ascites fluids were cleared by centrifugation and diluted 1:1 in 3 M NaCl/ 
1.5 m glycine (pH 8.9) and subjected to protein A affinity chromatography. 
Immunoglobulins were eluted by sequential application of 0.1 M sodium citrate 
buffers (pH 6, 5, 4, and 3).
Cation exchange chromatography was performed on a mono-S HR 5/5 
column (Pharmacia). Protein A-purificd material was dialyzed against 40 mM 
NaAc (pH 5.2) and loaded on the cation exchange column. Material was eluted 
with a 0 -400  mM linear LiCl gradient.
For hydroxylapatite (Bio-Rad Laboratories, Richmond, CA) purification, 
protein A-purified material was dialyzed against 10 mM sodium phosphate (pH 
6.8). The bound immunoglobulins were eluted with a linear ionic gradient 
ranging from 10 to 300 mM sodium phosphate (pH 6.8).
Results
Anti-DTPA Antibodies. F usion  o f  spleen cells from  mice im m u­
nized with In- or Y -D T PA -derived  K L H  with S p2 /0 -A g l4  m yelom a 
cells resulted in hybridom a cells secreting im m unoglobulins reactive 
with In-D TPA -B SA  and Y -D T P A -B S A . No reactivity was observed 
with BSA, indicating recognition  o f  DTPA, After subcloning, five 
hybridom as w ere selected: D T In l  (IgG 2 a), D TIn2 (IgG l), DTIn3 
(IgG l) , DTIn4 (Ig G l) , and D T Y 4  (IgG2a).
Metal Selectivity of the Anti-DTPA Antibodies. To study 
w hether the binding o f D T P A  w as  in fluenced  by  chelation of different 
metals, com petitive an tigen-b ind ing  E L IS A s were performed. For all 
anti-D TPA  M Abs, with the  excep tion  o f  D TIn3, In-DTPA was the 
best competitor for In -D T P A -B S A  binding, irrespective o f the origin 
o f the anti-DTPA M Ab; Le,, even  D T Y 4, iso lated  after immunization 
with Y-D TPA -K LH , show ed  superio r  b inding  o f In-DTPA. However, 
all m etal-D TPA  chelates, inc lud ing  Y -D T PA , com peted for In- 
D TPA -B SA  binding. For D TIn3, C r-D T P A  w as the best com petitor 
for In-D TPA -B SA  binding, bu t all chelates com peted for In-DTPA- 
B SA  binding. As an exam ple, the  com petitive  antigen-binding assay 
of D TIn2 is show n in Fig. 1.
C h e la te  Specificity of Anti-DTPA Antibodies. T he fine specific­
ity o f  the anti-DTPA M A bs w as de term ined  in  direct antigen-binding 
assays. Ail antibodies reacted w ith  p ro te in -con jugated  In-DTPA. In 
addition, D T In l,  DTIn2, D TIn4, and  D T Y 4  reacted  with protein- 
conjugate d-ITC -B z-D O T A. D Tln3 and  D T Y 4  reacted  with protein- 
conjugated ITC-Bz-D TPA . D T P A -B S A  binding o f  DTIn3 and DTY4 
could be inhibited com pletely w ith  ED TA .
Affinity Constants of Anti-DTPA Antibodies. Based on Scat­
chard analysis the affinity constants o f the an ti-D T PA  M A bs for 
binding n i In-DTPA ranged from  0.19 to 0.23 nM- 1 . The affinity 
constants o f bsM A b G250 X D T Y 4 and bsM A b G 250  X D T In l were 
com parable to the parental antibodies D T Y 4 and D T In l ,  respectively 
(Table 1).
Production of bsMAbs. Fusion  o f  hypoxan th ine  guanidine phos- 
phoribosyl transferase-deficient an ti-D T PA  hybridom a ceils with thy-
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Fig. I. Competitive antigen-binding assay of DTIn2. The amount of DTin2 bound to 
the solid-phase-coaled In-DTPA-BSA is plotted versus the concentration of the competing 
chelate added.
5865s
ANTI-REN Al, CELL CARCINOM A x  
Table 1 Affinity constants for hitidini; 111 In-DTPA
MAb Affinity constant (nst 1)
DTInl 0.23
DTInZ 0.23
DTIn3 ND"
DTIn4 0.19
DTY4 0.22
G250 X DTY4 0.28
G250 X DTIn2 NDU
G250 x  DTIn 1 0.24
11 ND, not determined.
midine kinase-deficient hybridoma G250 resulted in viable quadroma 
colonies. Quadromas G250 (IgGl) X DTY4, G250 (IgGl) X DTIn2, 
and G250 (IgG l) X DTInl produced bsMAbs, as evidenced by 
reactivity in the double-specificity ELISA. Fusion of G250 (IgG2b) 
with DTIn3 and G250 (IgGl) with DTIn3 resulted in quadroma cells 
that did not produce detectable levels of bsMAbs, as judged by the 
double-specificity assay. The IgG molecules produced by the 
quadroma G250 (IgG2b) X DTIn3 were partly characterized. IgG 
molecules with functional G25Q-binding pockets and nonfunctional 
DTIn3-binding pockets were produced, as well as IgG molecules with 
intact DTIn3 sites and nonfunctional G250 sites, as determined 
in ELISAs determining solid-phase binding to either NUH82 or 
BSA-DTPA using anti-IgGi or anti~IgG2b as the tracer antibody, 
respectively.
Purification of Antibodies. BsMAb G250 X  DTY4 was purified 
from ascites fluid using protein A chromatography followed by cation 
exchange chromatography (Fig. 2). Protein A-bound bsIgG was eluted 
at pH 5 (Fig. 2A) and subjected to cation exchange chromatography. 
Application of a LiCl gradient resulted in four protein peaks (Fig. 2 B \  
which were analyzed for G250 X DTY4 activity. bsG250 X DTY4 
antibody eluted at 223 mM LiCl. The cation exchange-purified mate­
rial represented 10-15% of the IgG eluted from the protein A column. 
The protein peak eluting at 206 mM LiCl contained immunoglobulins 
with intact IgGl X IgG2a heavy-chain pairing, as shown by a mixed- 
isotype ELISA, but incorrect heavy-1 ight-chain pairing, as shown by 
the negative reactivity in the double-specificity assay, resulting in 
nonfunctional binding pockets.
bsMAb G250 X DTIn2 was purified from ascites using protein A 
chromatography followed by hydroxyl apatite chromatography and 
cation exchange chromatography. After protein A chromatography, 
the material eluting at pH 6 contained bsMAb. This material separated 
into four peaks on hydroxyl apatite chromatography, with the bsMAb 
eluting at 133 mM phosphate. Additional separation of bsMAb from 
contaminants was achieved by cation exchange chromatography, with 
G250 X DTIn2 activity eluting at 165 mM LiCl. The cation exchange 
chromatography-purified material represented 10-15%  of the initial 
amount o f protein A-bound IgG.
BsMAb G250 X DTInl was purified from ascites fluid using 
protein A affinity chromatography followed by cation exchange chro­
matography. Protein A-bound bsIgG eluted at pH 5 and was subjected 
to cation exchange chromatography. This material separated into 
seven peaks, with the bsMAb eluting at 276 mM LiCl. The cation 
exchange chromatography-purified material represented 10-15%  of 
the protein A-bound IgG.
Discussion
Two-step strategies using bsMAbs may optimize radioimmunotar­
geting of tumors in vivo. The main advantage of this approach is the 
very rapid excretion of the low-molecular-weight radiolabeled ligand 
when not targeted to the tumor. Several preclinical and clinical studies 
have shown that two-phase targeting results in high tumor:nontumor
ratios shortly after injection of the radiolabel (11-15). To investigate 
the possibilities of two-phase radioimmunotargeting, we have devel­
oped five hybridomas producing MAbs reactive with DTPA and fused 
these with the hybridoma G250, producing a MAb reactive with renal
cell carcinoma, to obtain bsMAbs.
The affinity constants of the anti-DTPA MAbs for binding lll ln. 
DTPA were in the same order of magnitude (0 .19 -0 .23  n M ~ l) as 
reported for other antichelate MAbs (12, 26).
All anti-DTPA MAbs reacted also with DTPA loaded with different 
metals. For all anti-DTPA MAbs, with the exception of DTIn3, 
In-DTPA was bound most efficiently, irrespective of the immunogen 
used (In-DTPA-KLH or Y-DTPA-KLH). In the competitive binding 
assays, the affinity for binding In-DTPA was 10-100-fold  higher than 
the affinity for binding DTPA loaded with other metals. Similar 
results have been obtained by Reardan et al. (26) and Bosslet et al.
(27). They showed that the affinity of their antichelate antibodies for 
chelates labeled with indium was at least 100-fold higher than for 
chelates labeled with other metals. Involvement of In3+ in the anti- 
body-antigen interaction may cause the higher affinity of the MAbs 
for the In3+^labeled chelates (28)- 
The anti-In-DTPA MAbs displayed a remarkable chelate specific­
ity, The chelates recognized by D TInl, DTIn2, and DTIn4 (DTPA and
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pH
195 200 205 210 215 220 225 230 
LiCl concentration (mM)
Fig. 2. Purification of bsMAb G250 X DTY4 using protein A affinity chromatography 
(A) followed by cation exchange chromatography (fl). A, protein A-bound material was 
eluted by sequential application of 0.1 m sodium citrate buffers (pH 6, 5, 4, and 3). Bt 
cation exchange-bound, protein A-purified material was eluted using a 0-400  mM LiCl 
gradient in 40 mM NaAc (pH 5.2). The peaks containing bsMAb are indicated by the 
solid bar.
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ITC-Bz-DOTA) share an N (N > d iace tic  acid group, whereas the 
chelates recognized by DTIn3 (DTPA, ITC-Bz~DTPA, and EDTA) 
share an N '-acctic  acid group, suggesting the presence of different 
essen tia l structures within the D TPA molecule that determine the 
reactivity of the anti-In-DTPA M Abs. For the anti-Y-DTPA M Ab 
DTY4 (reacting with DTPA, ITC-Bz-DTPA, ITC-Bz-DOTA, and 
EDTA) the recognized structure is unclear. The broad reactivity of the 
MAbs makes them suitable for imaging (using 1 IlIn-DTPA or 
1)9 ,nTc-DTPA) as well as therapy (with tJ(iY-DTPA or yoY-DOTA).
Because o f  these characteristics, all anti-DTPA MAbs were used 
for production o f bsMAbs. Three of five quadroma fusions resulted in 
quadromas actually secreting bsMAbs. Fusion o f isotype-mismatched 
or isotype-matched hybridomas G250 and DTIn3 did not result in the 
production o f  functional bsMAb. Therefore, it seems that for success­
ful assembly o f bsM Ab, factors other than the isotype of the parental 
antibodies are important.
individual purification protocols were developed for every bsMAb. 
bsMAb G250 X D TY4 was purified using protein A affinity chro­
matography followed by cation exchange chromatography. The 
amount of bsM A b obtained after cation exchange chromatography 
was 10-15%  o f the total amount o f IgG present in the ascites fluid. 
bsMAb G250 X DTIn2 was purified by protein A affinity chroma- 
tography followed by hydroxylapatite chromatography and cation 
exchange chromatography. Similarly, bsM Ab G250 X DTIn2 also 
represented 10-15%  o f the total amount o f IgG present in the ascites 
fluid. After protein A affinity chromatography and cation exchange 
chromatography, bsM Ab G250 X D TInl was shown to be 10-15%  of 
the amount o f  IgG present in the ascites fluid. This is in concordance 
with total random  association o f the two heavy and light chains 
(provided that the heavy and light chains of both parents are expressed 
codominantly) as suggested by Suresh et til (29).
We have developed five anti-DTPA MAbs reactive with a broad 
range of chelated metals. Fusion o f the anti-DTPA-producing hybri­
domas with the G250 hybridoma resulted in three quadroma cell lines 
producing bsM Abs. These purified bsM Abs will allow testing and 
optimization of a two-phase targeting protocol in nude mice models.
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